Search

Your search keyword '"Voog, Eric"' showing total 290 results
Start Over Author "Voog, Eric"
290 results on '"Voog, Eric"'

51. Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Author

Garderet, Laurent, primary, Kuhnowski, Frédérique, additional, Berge, Benoit, additional, Roussel, Murielle, additional, Escoffre-Barbe, Martine, additional, Lafon, Ingrid, additional, Facon, Thierry, additional, Leleu, Xavier, additional, Karlin, Lionel, additional, Perrot, Aurore, additional, Moreau, Philippe, additional, Marit, Gerald, additional, Stoppa, Anne-Marie, additional, Royer, Bruno, additional, Chaleteix, Carine, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Lenain, Pascal, additional, Macro, Margaret, additional, Voog, Eric G., additional, Benboubker, Lotfi, additional, Allangba, Olivier Thierry, additional, Jourdan, Eric, additional, Orsini-Piocelle, Frédérique, additional, Brechignac, Sabine, additional, Eveillard, Jean-Richard, additional, Belhadj, Karim, additional, Wetterwald, Marc, additional, Pegourie, Brigitte, additional, Jaccard, Arnaud, additional, Eisenmann, Jean Claude, additional, Glaisner, Sylvie, additional, Mohty, Mohamad, additional, Hulin, Cyrille, additional, Avet Loiseau, Herve, additional, Mathiot, Claire, additional, and Attal, Michel, additional

Published
2021
Full Text
View/download PDF

52. Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Author

Richardson, Paul G., primary, Facon, Thierry, additional, Venner, Christopher P., additional, Bahlis, Nizar J., additional, Offner, Fritz, additional, White, Darrell, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Rigaudeau, Sophie, additional, Voog, Eric, additional, Yoon, Sung-Soo, additional, Suzuki, Kenshi, additional, Shibayama, Hirohiko, additional, Zhang, Xiaoquan, additional, Kumar, Arun, additional, Twumasi-Ankrah, Philip, additional, Labotka, Richard, additional, Rifkin, Robert M., additional, Lonial, Sagar, additional, Kumar, Shaji, additional, Rajkumar, S. Vincent, additional, and Moreau, Philippe, additional

Published
2021
Full Text
View/download PDF

53. MP41-12 AVELUMAB FIRST-LINE MAINTENANCE PLUS BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF TIME TO END OF NEXT-LINE THERAPY IN JAVELIN BLADDER 100

Author

Grivas, Petros, primary, Park, Se Hoon, additional, Voog, Eric, additional, Kopyltsov, Evgeny, additional, Gurney, Howard, additional, Borges Muniz, David Queiroz, additional, Rolland, Frédéric, additional, Als, Anne Birgitte, additional, Valderrama, Begoña P, additional, Wang, Jing, additional, Costa, Nuno, additional, Laliberte, Robert J, additional, di Pietro, Alessandra, additional, Powles, Thomas, additional, and Bellmunt, Joaquim, additional

Published
2021
Full Text
View/download PDF

54. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Author

Loehr, Andrea, Patnaik, Akash, Campbell, David, Shapiro, Jeremy, Bryce, Alan H., McDermott, Ray, Sautois, Brieuc, Vogelzang, Nicholas J., Bambury, Richard M., Voog, Eric, Zhang, Jingsong, Piulats, Josep M., Hussain, Arif, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Higano, Celestia S., Krieger, Laurence E., Sternberg, Cora N., Watkins, Simon P., Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, Abida, Wassim, Loehr, Andrea, Patnaik, Akash, Campbell, David, Shapiro, Jeremy, Bryce, Alan H., McDermott, Ray, Sautois, Brieuc, Vogelzang, Nicholas J., Bambury, Richard M., Voog, Eric, Zhang, Jingsong, Piulats, Josep M., Hussain, Arif, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Higano, Celestia S., Krieger, Laurence E., Sternberg, Cora N., Watkins, Simon P., Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, and Abida, Wassim

Abstract

Purpose: The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic BRCA1 or BRCA2 (BRCA) alteration. While sequencing of tumor tissue is considered the standard for identifying patients with BRCA alterations (BRCA(+)), plasma profiling may provide a minimally invasive option to select patients for rucaparib treatment. Here, we report dinical efficacy in patients with BRCA(+) mCRPC identified through central plasma, central tissue, or local genomic testing and enrolled in TRITON2. Patients and Methods: Patients had progressed after next-generation androgen receptor-directed and taxane-based therapies for mCRPC and had BRCA alterations identified by central sequencing of plasma and/or tissue samples or local genomic testing. Concordance of plasma/tissue BRCA status and objective response rate and prostate-specific antigen (PSA) response rates were summarized. Results: TRITON2 enrolled 115 patients with BRCA(+) identified by central plasma (n = 34), central tissue (n = 37), or local (n = 44) testing. Plasma/tissue concordance was determined in 38 patients with paired samples and was 47% in 19 patients with a somatic BRCA alteration. No statistically significant differences were observed between objective and PSA response rates to rucaparib across the 3 assay groups. Patients unable to provide tissue samples and tested solely by plasma assay responded at rates no different from patients identified as BRCA(+) by tissue testing. Conclusions: Plasma, tissue, and local testing of mCRPC patients can be used to identify men with BRCA(+) mCRPC who can benefit from treatment with the PARP inhibitor rucaparib.

Published
2021

55. ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

Author

Colomba, Emeline, primary, Jonas, Sarah Flora, additional, Eymard, Jean-Christophe, additional, Delva, Remy, additional, Brachet, Pierre-Emmanuel, additional, Neuzillet, Yann, additional, Penel, Nicolas, additional, Roubaud, Guilhem, additional, Bompas, Emmanuelle, additional, Mahammedi, Hakim, additional, Longo, Raffaele, additional, Helissey, Carole, additional, Barthelemy, Philippe, additional, Borchiellini, Delphine, additional, Hasbini, Ali, additional, Priou, Franck, additional, Saldana, Carolina, additional, Voog, Eric, additional, Foulon, Stéphanie, additional, and Fizazi, Karim, additional

Published
2021
Full Text
View/download PDF

56. Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

Author

Grivas, Petros, primary, Park, Se Hoon, additional, Voog, Eric, additional, Kopyltsov, Evgeny, additional, Gurney, Howard, additional, Muniz, David Queiroz Borges, additional, Rolland, Frederic, additional, Als, Anne Birgitte, additional, Valderrama, Begoña P., additional, Wang, Jing, additional, Costa, Nuno Matos, additional, Laliberte, Robert J, additional, Di Pietro, Alessandra, additional, Powles, Thomas, additional, and Bellmunt, Joaquim, additional

Published
2021
Full Text
View/download PDF

57. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Author

Facon, Thierry, primary, Venner, Christopher P., additional, Bahlis, Nizar J., additional, Offner, Fritz, additional, White, Darrell J., additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Rigaudeau, Sophie, additional, Rodon, Philippe, additional, Voog, Eric, additional, Yoon, Sung-Soo, additional, Suzuki, Kenshi, additional, Shibayama, Hirohiko, additional, Zhang, Xiaoquan, additional, Twumasi-Ankrah, Philip, additional, Yung, Godwin, additional, Rifkin, Robert M., additional, Moreau, Philippe, additional, Lonial, Sagar, additional, Kumar, Shaji K., additional, Richardson, Paul G., additional, and Rajkumar, S. Vincent, additional

Published
2021
Full Text
View/download PDF

58. Sarcopenia in metastatic cancer patients: results of a prospective non-randomized study.

Author

DUBU, Jonas, primary, SEPTANS, Anne-Lise, additional, DOMONT, Julien, additional, BOURGEOIS, Hugues, additional, DUPUIS, Olivier, additional, RUFFIER, Amandine, additional, VOOG, Eric, additional, POINTREAU, Yoann, additional, ROCHE, Sophie, additional, SERRE, Lydie, additional, RABI, Hassan, additional, DENIS, Fabrice, additional, and DÛ, Katell LE, additional

Published
2021
Full Text
View/download PDF

59. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma

Author

Powels Thomas, Hoon Park Se, Voog Eric, Caserta Claudia, Valderrama Begona P, Gurney Howard, Kalofonos Haralabos, Radulović Sinisa, Dermay Wim, Ullen Anders, Lariot Yohann, and Sridhar Srikala S

Subjects
Avelumab, Advanced or Metastatic Urothelial Carcinoma, chemotherapy
Abstract

BACKGROUND.Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. METHODS.In a phase 3 trial, we randomly assigned patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (four to six cycles of gemcitabine plus cisplatin or carboplatin) to receive best supportive care with or without maintenance avelumab. The primary end point was overall survival, assessed among all patients who underwent randomization (overall population) and among those with tumors positive for programmed cell death ligand 1 (PD-L1). Secondary end points included progression-free survival and safety. RESULTS.Among all 700 patients who underwent randomization, the addition of maintenance avelumab to best supportive care significantly prolonged overall survival as compared with best supportive care alone (control). Overall survival at 1 year was 71.3% in the avelumab group and 58.4% in the control group (median overall survival, 21.4 months vs. 14.3 months; hazard ratio for death, 0.69; 95% confidence interval [CI], 0.56 to 0.86; P=0.001). Avelumab also significantly prolonged overall survival in the PD-L1–positive population; overall survival at 1 year was 79.1% in the avelumab group and 60.4% in the control group (hazard ratio, 0.56; 95% CI, 0.40 to 0.79; P CONCLUSIONSMaintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Bladder 100 ClinicalTrials.gov number,NCT02603432. opens in new tab.)

Published
2020

60. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

Author

Abida, Wassim, Patnaik, Akash, Campbell, David, Shapiro, Jeremy, Bryce, Alan H., McDermott, Ray, Sautois, Brieuc, Vogelzang, Nicholas J., Bambury, Richard M., Voog, Eric, Zhang, Jingsong, Piulats, Josep M., Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Higano, Celestia S., Krieger, Laurence E., Sternberg, Cora N., Watkins, Simon P., Despain, Darrin, Simmons, Andrew D., Loehr, Andrea, Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, Abida, Wassim, Patnaik, Akash, Campbell, David, Shapiro, Jeremy, Bryce, Alan H., McDermott, Ray, Sautois, Brieuc, Vogelzang, Nicholas J., Bambury, Richard M., Voog, Eric, Zhang, Jingsong, Piulats, Josep M., Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Higano, Celestia S., Krieger, Laurence E., Sternberg, Cora N., Watkins, Simon P., Despain, Darrin, Simmons, Andrew D., Loehr, Andrea, Dowson, Melanie, Golsorkhi, Tony, and Chowdhury, Simon

Abstract

PURPOSEBRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study.METHODSWe enrolled patients who progressed after one to two lines of next-generation androgen receptor-directed therapy and one taxane-based chemotherapy for mCRPC. Efficacy and safety populations included patients with a deleterious BRCA alteration who received >= 1 dose of rucaparib. Key efficacy end points were objective response rate (ORR; per RECIST/Prostate Cancer Clinical Trials Working Group 3 in patients with measurable disease as assessed by blinded, independent radiology review and by investigators) and locally assessed prostate-specific antigen (PSA) response (>= 50% decrease from baseline) rate.RESULTSEfficacy and safety populations included 115 patients with a BRCA alteration with or without measurable disease. Confirmed ORRs per independent radiology review and investigator assessment were 43.5% (95% CI, 31.0% to 56.7%; 27 of 62 patients) and 50.8% (95% CI, 38.1% to 63.4%; 33 of 65 patients), respectively. The confirmed PSA response rate was 54.8% (95% CI, 45.2% to 64.1%; 63 of 115 patients). ORRs were similar for patients with a germline or somatic BRCA alteration and for patients with a BRCA1 or BRCA2 alteration, while a higher PSA response rate was observed in patients with a BRCA2 alteration. The most frequent grade >= 3 treatment-emergent adverse event was anemia (25.2%; 29 of 115 patients).CONCLUSIONRucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.

Published
2020

61. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Author

Donskov, Frede, Motzer, Robert R.J., Voog, Eric, Hovey, Elizabeth, Grüllich, Carsten, Nott, Louise L.M., Cuff, Katharine, Gil, Thierry, Jensen, Niels Viggo, Chevreau, Christine, Negrier, Sylvie, Depenbusch, Reinhard, Bergmann, Lothar, Cornelio, Izzy, Champsaur, Anne, Escudier, Bernard, Pal, Sumanta, Powles, Thomas Bartholomew T., Choueiri, Toni T.K., Donskov, Frede, Motzer, Robert R.J., Voog, Eric, Hovey, Elizabeth, Grüllich, Carsten, Nott, Louise L.M., Cuff, Katharine, Gil, Thierry, Jensen, Niels Viggo, Chevreau, Christine, Negrier, Sylvie, Depenbusch, Reinhard, Bergmann, Lothar, Cornelio, Izzy, Champsaur, Anne, Escudier, Bernard, Pal, Sumanta, Powles, Thomas Bartholomew T., and Choueiri, Toni T.K.

Abstract

Background: Cabozantinib improved progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy in the phase III METEOR trial (NCT01865747). Limited data are available on the use of targeted therapies in older patients with advanced RCC. Methods: Efficacy and safety in METEOR were retrospectively analysed for three age subgroups: <65 (n = 394), 65–74 (n = 201) and ≥75 years (n = 63). Results: PFS, OS and ORR were improved with cabozantinib compared with everolimus in all age subgroups. The PFS hazard ratios (HRs) were 0.53 (95% confidence interval [CI]: 0.41–0.68), 0.53 (95% CI: 0.37–0.77) and 0.38 (95% CI: 0.18–0.79) for <65, 65–74 and ≥75 years, respectively, and the OS HRs were 0.72 (95% CI: 0.54–0.95), 0.66 (95% CI: 0.44–0.99) and 0.57 (95% CI: 0.28–1.14). The ORR for cabozantinib versus everolimus was 15% vs 5%, 21% vs 2% and 19% vs 0%, respectively. No significant differences were observed in PFS or OS with age as a categorical or continuous variable. Grade III/IV adverse events (AEs) were generally consistent across subgroups, although fatigue, hypertension and hyponatraemia occurred more frequently in older patients treated with cabozantinib. Dose reductions to manage AEs were more frequent in patients receiving cabozantinib than in those receiving everolimus. Dose reductions and treatment discontinuation due to AEs were more frequent in older patients in both treatment groups. Conclusions: Cabozantinib improved PFS, OS and ORR compared with everolimus in previously treated patients with advanced RCC, irrespective of age group, supporting use in all age categories. Proactive dose modification and supportive care may help to mitigate AEs in older patients while maintaining efficacy., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2020

63. Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).

Author

Abida, Wassim, primary, Patnaik, Akash, additional, Campbell, David, additional, Shapiro, Jeremy David, additional, Bryce, Alan Haruo, additional, McDermott, Raymond S., additional, Sautois, Brieuc, additional, Vogelzang, Nicholas J., additional, Bambury, Richard M, additional, Voog, Eric, additional, Zhang, Jingsong, additional, Piulats, Josep M., additional, Ryan, Charles J., additional, Merseburger, Axel Stuart, additional, Fizazi, Karim, additional, Despain, Darrin, additional, Loehr, Andrea, additional, Dowson, Melanie, additional, Golsorkhi, Tony, additional, and Chowdhury, Simon, additional

Published
2021
Full Text
View/download PDF

64. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est dʼEtude des Leucémies et Autres Maladies du Sang

Author

Gimenez, Estelle, Chauvet, Martine, Rabin, Laetitia, Puteaud, Isabelle, Duley, Samuel, Hamaidia, Sieme, Bruder, Juliana, Rolland-Neyret, Valérie, Le Gouill, Steven, Tournilhac, Olivier, Voog, Eric, Maisonneuve, Hervé, Jacob, Marie C., Leroux, Dominique, Béné, Marie C., Formisano-Tréziny, Christine, Gabert, Jean, Gressin, Rémy, and Callanan, Mary B.

Published
2012
Full Text
View/download PDF

65. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Author

Powles, Thomas, primary, Park, Se Hoon, additional, Voog, Eric, additional, Caserta, Claudia, additional, Valderrama, Begoña P., additional, Gurney, Howard, additional, Kalofonos, Haralabos, additional, Radulović, Siniša, additional, Demey, Wim, additional, Ullén, Anders, additional, Loriot, Yohann, additional, Sridhar, Srikala S., additional, Tsuchiya, Norihiko, additional, Kopyltsov, Evgeny, additional, Sternberg, Cora N., additional, Bellmunt, Joaquim, additional, Aragon-Ching, Jeanny B., additional, Petrylak, Daniel P., additional, Laliberte, Robert, additional, Wang, Jing, additional, Huang, Bo, additional, Davis, Craig, additional, Fowst, Camilla, additional, Costa, Nuno, additional, Blake-Haskins, John A., additional, di Pietro, Alessandra, additional, and Grivas, Petros, additional

Published
2020
Full Text
View/download PDF

66. MM-347: Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial

Author

Facon, Thierry, primary, Venner, Christopher P., additional, Bahlis, Nizar J., additional, Attal, Michel, additional, Offner, Fritz, additional, White, Darrell J., additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Rigaudeau, Sophie, additional, Rodon, Philippe, additional, Voog, Eric, additional, Yoon, Sung-Soo, additional, Suzuki, Kenshi, additional, Shibayama, Hirohiko, additional, Zhang, Xiaoquan, additional, Yung, Godwin, additional, Rifkin, Robert M., additional, Moreau, Philippe, additional, Lonial, Sagar, additional, Kumar, Shaji K., additional, Richardson, Paul G., additional, and Rajkumar, S. Vincent, additional

Published
2020
Full Text
View/download PDF

67. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.

Author

Powles, Thomas, primary, Park, Se Hoon, additional, Voog, Eric, additional, Caserta, Claudia, additional, Valderrama, B.P., additional, Gurney, Howard, additional, Kalofonos, Haralabos, additional, Radulovic, Sinisa, additional, Demey, Wim, additional, Ullén, Anders, additional, Loriot, Yohann, additional, Sridhar, Srikala S., additional, Tsuchiya, Norihiko, additional, Kopyltsov, Evgeny, additional, Sternberg, Cora N., additional, Bellmunt, Joaquim, additional, Aragon-Ching, Jeanny B., additional, Petrylak, Daniel Peter, additional, di Pietro, Alessandra, additional, and Grivas, Petros, additional

Published
2020
Full Text
View/download PDF

68. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Author

Abida, Wassim, primary, Campbell, David, additional, Patnaik, Akash, additional, Shapiro, Jeremy D., additional, Sautois, Brieuc, additional, Vogelzang, Nicholas J., additional, Voog, Eric G., additional, Bryce, Alan H., additional, McDermott, Ray, additional, Ricci, Francesco, additional, Rowe, Julie, additional, Zhang, Jingsong, additional, Piulats, Josep Maria, additional, Fizazi, Karim, additional, Merseburger, Axel S., additional, Higano, Celestia S., additional, Krieger, Laurence E., additional, Ryan, Charles J., additional, Feng, Felix Y., additional, Simmons, Andrew D., additional, Loehr, Andrea, additional, Despain, Darrin, additional, Dowson, Melanie, additional, Green, Foad, additional, Watkins, Simon P., additional, Golsorkhi, Tony, additional, and Chowdhury, Simon, additional

Published
2020
Full Text
View/download PDF

69. Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101.

Author

Bilen, Mehmet Asim, primary, Rini, Brian I., additional, Motzer, Robert J., additional, Larkin, James M. G., additional, Haanen, John B. A. G., additional, Albiges, Laurence, additional, Pagliaro, Lance C., additional, Voog, Eric, additional, Lam, Elaine Tat, additional, Kislov, Nikolai, additional, McGregor, Bradley Alexander, additional, Huang, Bo, additional, di Pietro, Alessandra, additional, Krulewicz, Stan, additional, and Choueiri, Toni K., additional

Published
2020
Full Text
View/download PDF

70. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Author

Donskov, Frede, primary, Motzer, Robert J., additional, Voog, Eric, additional, Hovey, Elizabeth, additional, Grüllich, Carsten, additional, Nott, Louise M., additional, Cuff, Katharine, additional, Gil, Thierry, additional, Jensen, Niels Viggo, additional, Chevreau, Christine, additional, Negrier, Sylvie, additional, Depenbusch, Reinhard, additional, Bergmann, Lothar, additional, Cornelio, Izzy, additional, Champsaur, Anne, additional, Escudier, Bernard, additional, Pal, Sumanta, additional, Powles, Thomas, additional, and Choueiri, Toni K., additional

Published
2020
Full Text
View/download PDF

72. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V, Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M, Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves-Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J, Lipkin, Steven M, McKay, James D, Dumontet, Charles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V, Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M, Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves-Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J, Lipkin, Steven M, McKay, James D, and Dumontet, Charles

Abstract

To the Editor, Multiple myeloma (MM) is the third most common hematological malignancy, after Non-Hodgkin Lymphoma and Leukemia. MM is generally preceded by Monoclonal Gammopathy of Undetermined Significance (MGUS) [1], and epidemiological studies have identified older age, male gender, family history, and MGUS as risk factors for developing MM [...]

Published
2019

73. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Author

Leleu, Xavier, Fouquet, Guillemette, Richez, Valentine, Guidez, Stéphanie, Duhamel, Alain, Machuron, François, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean Valère, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Pétillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chrétien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G, Attal, Michel, Moreau, Philippe, Avet-Loiseau, Herve, Hulin, Cyrille, Facon, Thierry, Leleu, Xavier, Fouquet, Guillemette, Richez, Valentine, Guidez, Stéphanie, Duhamel, Alain, Machuron, François, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean Valère, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Pétillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chrétien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G, Attal, Michel, Moreau, Philippe, Avet-Loiseau, Herve, Hulin, Cyrille, and Facon, Thierry

Abstract

Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

77. Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients

Author

Voog, Eric, primary, Campillo‐Gimenez, Boris, additional, Elkouri, Claude, additional, Priou, Franck, additional, Rolland, Frederic, additional, Laguerre, Brigitte, additional, Elhannani, Chaza, additional, Merrer, Jacques, additional, Pfister, Christian, additional, Sevin, Emmanuel, additional, L'Haridon, Tifenn, additional, Hasbini, Ali, additional, Moise, Laura, additional, Le Rol, Annick, additional, Malhaire, Jean Pierre, additional, Delva, Remy, additional, Vauléon, Elodie, additional, Cojocarasu, Oana, additional, Deguiral, Philippe, additional, Cumin, Isabelle, additional, Cheneau, Caroline, additional, Schlürmann, Friedrike, additional, Delecroix, Valérie, additional, Boughalem, Elouen, additional, Mollon, Delphine, additional, Ligeza‐Poisson, Catherine, additional, Abadie‐Lacourtoisie, Sophie, additional, Monpetit, Erik, additional, Chatellier, Thierry, additional, Desclos, Henry, additional, Coquan, Elodie, additional, Joly, Florence, additional, Tessereau, Jean Yves, additional, Dupuy, Sandra, additional, Déniel Lagadec, Delphine, additional, Marhuenda, Fanny, additional, and Grudé, Francoise, additional

Published
2019
Full Text
View/download PDF

78. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

Author

Leleu, Xavier, primary, Fouquet, Guillemette, additional, Richez, Valentine, additional, Guidez, Stéphanie, additional, Duhamel, Alain, additional, Machuron, François, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Malfuson, Jean-Valère, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Roussel, Murielle, additional, Jaccard, Arnaud, additional, Pétillon, Marie-Odile, additional, Belhadj-Merzoug, Karim, additional, Lepeu, Gérard, additional, Chrétien, Marie-Lorraine, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Offner, Fritz, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Kuhnowski, Frédérique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamile, additional, Fitoussi, Olivier, additional, Roos-Weil, Damien, additional, Eisenmann, Jean-Claude, additional, Dorvaux, Véronique, additional, Voog, Eric G., additional, Attal, Michel, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Hulin, Cyrille, additional, and Facon, Thierry, additional

Published
2019
Full Text
View/download PDF

79. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy

Author

Oudard, Stéphane, primary, Latorzeff, Igor, additional, Caty, Armelle, additional, Miglianico, Laurent, additional, Sevin, Emmanuel, additional, Hardy-Bessard, Anne Claire, additional, Delva, Remy, additional, Rolland, Frédéric, additional, Mouret, Loic, additional, Priou, Franck, additional, Beuzeboc, Philippe, additional, Gravis, Gwenaelle, additional, Linassier, Claude, additional, Gomez, Philippe, additional, Voog, Eric, additional, Muracciole, Xavier, additional, Abraham, Christine, additional, Banu, Eugeniu, additional, Ferrero, Jean-Marc, additional, Ravaud, Alain, additional, Krakowski, Ivan, additional, Lagrange, Jean-Léon, additional, Deplanque, Gaël, additional, Zylberait, David, additional, Bozec, Laurence, additional, Houede, Nadine, additional, Culine, Stéphane, additional, and Elaidi, Reza, additional

Published
2019
Full Text
View/download PDF

81. Time to Improve Bortezomib and Lenalidomide Lines of Therapy

Author

Guidez, Stephanie, Moreau, Philippe, Leleu, Xavier, Caillot, Denis, Pegourie, Brigitte, Banos, Anne, Terpos, Evangelos, Facon, Thierry, Benboubker, Lofti, Macro, Margaret, Hulin, Cyrille, Karlin, Lionel, Royer, Bruno, Stoppa, Anne-Marie, Garderet, Laurent, Zweegman, Sonja, Chretien, Marie Lorraine, Voog, Eric, Abildgaard , Niels, Richez, Valentine, J. Jurczyszyn, Artur, Demarquette, Hélène, Lancesseur, Charles, Joao, Cristina, Ikhlef, Souhila, Le Du, Katell, and Gay, Francesca Marianatal

Published
2017

82. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a or Gene Alteration.

Author

Abida, Wassim, Patnaik, Akash, Campbell, David, Shapiro, Jeremy, Bryce, Alan H., McDermott, Ray, Sautois, Brieuc, Vogelzang, Nicholas J., Bambury, Richard M., Voog, Eric, Zhang, Jingsong, Piulats, Josep M., Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Higano, Celestia S., Krieger, Laurence E., and Sternberg, Cora N.

Published
2020
Full Text
View/download PDF

83. Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.

Author

Voog, Eric, Campillo‐Gimenez, Boris, Elkouri, Claude, Priou, Franck, Rolland, Frederic, Laguerre, Brigitte, Elhannani, Chaza, Merrer, Jacques, Pfister, Christian, Sevin, Emmanuel, L'Haridon, Tifenn, Hasbini, Ali, Moise, Laura, Le Rol, Annick, Malhaire, Jean Pierre, Delva, Remy, Vauléon, Elodie, Cojocarasu, Oana, Deguiral, Philippe, and Cumin, Isabelle

Subjects
RENAL cell carcinoma, INTERMEDIATE goods, PATIENT selection, RENAL cancer, PROTEIN-tyrosine kinases
Abstract

The treatment landscape in metastatic renal cell carcinoma has changed fundamentally over the last decade by the development of antiangiogenic agents, mammalian target of rapamycin inhibitors and immunotherapy. Outside of the context of a clinical trial, the treatments are used sequentially. We describe results under real‐life conditions of a sequential treatment strategy, before the era of immunotherapy. All patients were treated according to their prognostic score (either Memorial Sloan Kettering Cancer Center or International Metastatic Renal Cell Carcinoma Database Consortium) for advanced renal cell carcinoma. A treatment strategy involving 1 to 4 lines was determined including a rechallenge criterion for the repeat use of a treatment class. Three hundred forty‐four patients were included over 3 years. Overall survival was 57 months in patients with good or intermediate prognosis and 19 months in patients with poor prognosis. In the former group, the proportions of patients treated with 2 to 4 treatment lines were 70%, 38% and 16%, respectively. The best objective response rates for lines 1 to 4 were 46%, 36%, 16% and 17%, respectively. Grade III/IV toxicity did not appear to be cumulative. The recommended strategy was followed in 68% of patients. A large proportion of patients with good or intermediate prognosis who progress after two lines of treatment still have a performance status good enough to receive a systemic treatment, which justifies such a strategy. Overall survival of patients with good and intermediate prognosis was long, suggesting a benefit from the applied approach. These results might be used as selection criterion for the treatment of patients in the era of immune checkpoint inhibitors. What's new? Metastatic renal cancer is a notoriously relapsing disease that can be treated with anti‐angiogenic treatments, tyrosine kinase inhibitors, inhibitors of the mammalian Target of Rapamycin or immune checkpoint inhibitors. The authors performed a "real‐life" study testing a sequential strategy of the first three treatments applied to 344 patients with relapsing metastatic renal cancer before the era of immunotherapy. They found that the overall survival of patients with good and intermediate prognosis was long, almost 5 years, and plan a new study including immunotherapy in the future. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

84. Light Chain Escape in Multiple Myeloma

Author

Dejoie, Thomas, primary, Fouquet, Guillemette, additional, Hulin, Cyrille, additional, Roussel, Murielle, additional, Hebraud, Benjamin, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Tiab, Mourad, additional, Malfuson, Jean Valère, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Jaccard, Arnaud, additional, Belhadj, Karim, additional, Lepeu, Gérard, additional, Chretien, Marie Lorraine, additional, Caillot, Denis, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Pegourie, Brigitte, additional, Kuhnowski, Frederique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamilé, additional, Garderet, Laurent, additional, Roos-Weil, Damien, additional, Eisenmann, Jean Claude, additional, Dorvaux, Veronique, additional, Voog, Eric G., additional, Mathiot, Claire, additional, Fermand, Jean-Paul, additional, Facon, Thierry, additional, Avet-Loiseau, Hervé, additional, Harousseau, Jean Luc, additional, Moreau, Philippe, additional, Attal, Michel, additional, and Leleu, Xavier, additional

Published
2018
Full Text
View/download PDF

85. Pomalidomide 3rd Line Versus 4th Line for RRMM

Author

Gruchet, Cécile, primary, Guidez, Stephanie, additional, Richez, Valentine, additional, Hulin, Cyrille, additional, Voog, Eric G., additional, Perrot, Aurore, additional, Macro, Margaret, additional, Decaux, Olivier, additional, Pauline, Gueneau, additional, Caillot, Denis, additional, Stoppa, Anne-Marie, additional, Lenain, Pascal, additional, Lebreton, Pierre, additional, Royer, Bruno, additional, Lancesseur, Charles, additional, Laribi, Kamel, additional, Le Du, Katell, additional, Moulin, Charline, additional, Montes De Oca, Catalina, additional, Jaccard, Arnaud, additional, Benboubker, Lotfi, additional, Chaleteix, Carine, additional, Systchenko, Thomas, additional, Moya, Niels, additional, Sabirou, Florence, additional, Levy, Anthony, additional, Bobin, Arthur, additional, Franques, Paul, additional, Gardeney, Helene, additional, Tomowiak, Cecile, additional, Desmier, Deborah, additional, Machet, Antoine, additional, Avet Loiseau, Herve, additional, and Leleu, Xavier, additional

Published
2018
Full Text
View/download PDF

87. A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone

Author

Garderet, Laurent, primary, Kuhnowski, Frederique, additional, Mary, jean Yves, additional, Roussel, Murielle, additional, Escoffre-Barbe, Martine, additional, Lafon, Ingrid, additional, Facon, Thierry, additional, Karlin, Lionel, additional, Perrot, Aurore, additional, Moreau, Philippe, additional, Marit, Gerald, additional, Stoppa, Anne-Marie, additional, Marolleau, Jean-Pierre, additional, Chaleteix, Carine, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Lenain, Pascal, additional, Macro, Margaret, additional, Voog, Eric, additional, Benboubker, Lofti, additional, Allangba, Olivier, additional, Jourdan, Eric, additional, Mohty, Mohamad, additional, Avet Loiseau, Herve, additional, Mathiot, Claire, additional, and Attal, Michel, additional

Published
2017
Full Text
View/download PDF

88. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Weisel, Katja, Doyen, Chantal, Dimopoulos, Meletios, Yee, Adrian, Lahuerta, Juan José, Martin, Amber, Travers, Karin, Druyts, Eric, Toor, Kabirraaj, Abildgaard, Niels, Lu, Jin, Van Droogenbroeck, Jan, Geraldes, Catarina, Petrini, Mario, Voillat, Laurent, Voog, Eric, Facon, Thierry, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Weisel, Katja, Doyen, Chantal, Dimopoulos, Meletios, Yee, Adrian, Lahuerta, Juan José, Martin, Amber, Travers, Karin, Druyts, Eric, Toor, Kabirraaj, Abildgaard, Niels, Lu, Jin, Van Droogenbroeck, Jan, Geraldes, Catarina, Petrini, Mario, Voillat, Laurent, Voog, Eric, and Facon, Thierry

Abstract

In newly diagnosed multiple myeloma (MM), patients ineligible for front-line autologous stem cell transplantation (ASCT), melphalan and prednisone (MP) with thalidomide (MPT) or bortezomib (VMP) are standard first-line therapeutic options. Despite new treatment regimens incorporating bortezomib or lenalidomide, MM remains incurable. The FIRST study demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) for the combination of lenalidomide and low-dose dexamethasone (Rd) until progression vs. MPT in transplant-ineligible ndMM patients. However, to date no head-to-head randomized controlled trials (RCTs) have compared Rd or MPT versus VMP. We conducted a network meta-analysis using RCTs identified through a systematic literature review to evaluate the relative efficacy of Rd versus other regimens on survival endpoints in previously untreated MM patients ineligible for ASCT. In this analysis, Rd was associated with a significant PFS and survival advantage versus other first-line treatments (VMP, MPT, MP), challenging the role of alkylators in this setting.

Published
2017

89. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL

Author

Leleu, Xavier, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, De Revel, Thierry, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gerard, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frederique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Weil, Damien Roos, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Hulin, Cyrille, Attal, Michel, Moreau, Philippe, Facon, Thierry, Service d'Hématologie, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Général de La Roche sur Yon, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pontchaillou [Rennes], Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Henri Duffaut (Avignon), Lipides - Nutrition - Cancer (U866) (LNC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Chalon-sur-Saône William Morey, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier de Meaux, Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Laboratoire d'Hématologie [Rangueil], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service d'Hématologie Clinique, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Claude Huriez [Lille], CHU Lille, Jonchère, Laurent, Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

WOS:000368020103223; International audience; Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015

Published
2015

90. Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer

Author

Voog, Eric, primary, Campion, Loïc, additional, du Rusquec, Pauline, additional, Bourgeois, Hugues, additional, Domont, Julien, additional, Denis, Fabrice, additional, Emmanuel, Eric, additional, Dupuis, Olivier, additional, Ganem, Gérard, additional, Lafont, Cedrik, additional, Le Du, Katell, additional, Pavluc, Elena, additional, Pointreau, Yohan, additional, Roche, Sophie, additional, Juhel-Voog, Laurence, additional, Zinger, Marie, additional, and Solal-Celigny, Philippe, additional

Published
2017
Full Text
View/download PDF

91. Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).

Author

Donskov, Frede, primary, Motzer, Robert J., additional, Voog, Eric, additional, Hovey, Elizabeth J., additional, Grüllich, Carsten, additional, Nott, Louise M., additional, Cuff, Katharine Ellen, additional, Gil, Thierry, additional, Jensen, Niels Viggo, additional, Chevreau, Christine, additional, Negrier, Sylvie, additional, Depenbusch, Reinhard, additional, Bergmann, Lothar, additional, Cornelio, Izzy, additional, Champsaur, Anne, additional, Escudier, Bernard J., additional, Pal, Sumanta K., additional, Powles, Thomas, additional, and Choueiri, Toni K., additional

Published
2017
Full Text
View/download PDF

92. IVOIRE: Results of a prospective multicentre cohort study in advanced renal carcinoma.

Author

Voog, Eric, primary, Campillo-Gimenez, Boris, additional, El Kouri, Claude, additional, Priou, Frank, additional, Rolland, Frederic, additional, Laguerre, Brigitte, additional, Elhannani, Chaza, additional, Merrer, Jacques, additional, Joly, Florence, additional, Pfister, Christian, additional, Malhaire, Jean-pierre, additional, Delva, Remy, additional, Cojocarasu, Oana, additional, Cumin, Isabelle, additional, Ligeza-poisson, Catherine, additional, Schlurmann, Friederike, additional, Monpetit, Erik, additional, Deniel Lagadec, Delphine, additional, Marhuenda, Fanny, additional, and Grude, Francoise, additional

Published
2017
Full Text
View/download PDF

93. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Author

Leleu, Xavier, primary, Fouquet, Guillemette, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Roussel, Muriel, additional, Jaccard, Arnaud, additional, Petillon, Marie-Odile, additional, Belhadj-Merzoug, Karim, additional, Lepeu, Gérard, additional, Chretien, Marie-Lorraine, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Kuhnowski, Frédérique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Frayfer, Jamile, additional, Fitoussi, Olivier, additional, Roos Weil, Damien, additional, Eisenmann, Jean-Claude, additional, Dorvaux, Véronique, additional, Voog, Eric, additional, Hulin, Cyrille, additional, and Attal, Michel, additional

Published
2017
Full Text
View/download PDF

94. IFM2012-03

Author

Leleu, Xavier, primary, Fouquet, Guillemette, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Malfuson, Jv, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Roussel, Murielle, additional, Jaccard, Arnaud, additional, Petillon, Marie-Odile, additional, Belhadj-Merzoug, Karim, additional, Lepeu, Gerard, additional, Chretien, Marie-Lorraine, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Offner, Fritz, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Kuhnowski, Frederique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamile, additional, Fitoussi, Olivier, additional, Roos Weil, Damien, additional, Eisenmann, Jean Claude, additional, Dorvaux, Veronique, additional, Voog, Eric G., additional, Hulin, Cyrille, additional, Attal, Michel, additional, Moreau, Philippe, additional, and Facon, Thierry, additional

Published
2016
Full Text
View/download PDF

95. Prospective study of a web-mediated management of febrile neutropenia related to chemotherapy (Bioconnect).

Author

Voog, Eric, Pointreau, Yoann, Bourgeois, Hugues, Le Du, Katell, Denis, Fabrice, and Seegers, Valérie

Subjects
*FEBRILE neutropenia, *WEB-based user interfaces, *PATIENT compliance, *LONGITUDINAL method, *PATIENT satisfaction, *THERAPEUTICS
Abstract

Background: We aimed to investigate whether patient self-evaluated symptoms transmitted via Internet is feasible between planned visits to provide an early management of fever and neutropenia induced by chemotherapy, and if it can reduce hospitalizations for severe neutropenia.Methods: Patients who received a chemotherapy regimen with an overall risk of febrile neutropenia ≥ 20% had to report daily temperature between physician planned visits using a web application. Fever and clinical signs of seriousness were reported to the physician (if some criteria were fulfilled in a specific algorithm) via automatic email notifications by the web application. Patients could be hospitalized quickly or could take over at home, make blood count, and take predefined oral antibiotics if indicated. Primary outcome was patient's compliance and satisfaction. The number and the cost of hospitalization were also assessed and compared with an historical cohort of patients with similar clinical conditions and treatment.Results: Among the 41 patients included, 36 (87.8%) used the web application with 88% of daily compliance and 90% (28/33) of satisfaction. One patient (2.7%) had planned hospitalization after the web application alert. In the historical cohort, the rate of unplanned hospitalization for febrile neutropenia was 17% (6 patients) and 2.7% (1 patient) in users of the web application cohort. The cumulative cost of hospitalization for neutropenia was USD 28,827 in the historical cohort and USD 6563 in the web application cohort.Conclusion: Web-mediated follow-up of febrile neutropenia is feasible. It led to high patient satisfaction, high compliance, and a possible reduction of the number and the cost of hospitalizations. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

96. Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study.

Author

Pegourie, Brigitte, Karlin, Lionel, Benboubker, Lotfi, Orsini‐Piocelle, Frédérique, Tiab, Mourad, Auger‐Quittet, Sophie, Rodon, Philippe, Royer, Bruno, Leleu, Xavier, Bareau, Benoit, Cliquennois, Manuel, Fuzibet, Jean‐Gabriel, Voog, Eric, Belhadj‐Merzoug, Karim, Decaux, Olivier, Rey, Philippe, Slama, Bohrane, Leyronnas, Cecile, Zarnitsky, Charles, and Boyle, Eileen

Published
2019
Full Text
View/download PDF

97. Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment

Author

Barthélémy, Philippe, Thibault, Constance, Fléchon, Aude, Gross-Goupil, Marine, Voog, Eric, Eymard, Jean-Christophe, Abraham, Christine, Chasseray, Matthieu, Lorgis, Véronique, Hilgers, Werner, Gobert, Aurélien, Le Moulec, Sylvestre, Simon, Camille, Nicolas, Emanuel, Escande, Anne, Pouessel, Damien, Mouillet, Guillaume, Josse, Constant, Solbes, Marie-Noelle, Lambert, Prisca, and Loriot, Yohann

Abstract

In this noninterventional study of avelumab first-line maintenance treatment in France, results were consistent with JAVELIN Bladder 100 phase 3 trial findings. In exploratory subgroup analyses, patients treated with avelumab followed by second-line enfortumab vedotin had encouraging long-term outcomes.

Published
2024
Full Text
View/download PDF

98. Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial

Author

Oudard, Stephane, Tran, Yohann, Helissey, Carole, Vauchier, Charles, Ratta, Raffaele, Bennamoun, Mostefa, Voog, Eric, Hasbini, Ali, Thiery-Vuillemin, Antoine, Aldabbagh, Kais, Saldana, Carolina, Sevin, Emmanuel, Amela, Eric, Von Amsberg, Gunhild, Houede, Nadine, Besson, Dominique, Feyerabend, Susan, Boegemann, Martin, Pfister, David, Schostak, Martin, Huillard, Olivier, Di Fiore, Frederic, Quivy, Amandine, Vernerey, Dewi, Falcoz, Antoine, Youcef-Ali, Karima, Kotti, Salma, Lepicard, Eve M., and Barthelemy, Philippe

Abstract

Little is known about the impact of biweekly cabazitaxel 16 mg/m2(CBZ q2w) plus prophylactic granulocyte colony-stimulating factor (G-CSF) on pain and health-related quality of life (HRQoL) compared with the standard regimen (25 mg/m2CBZ triweekly) plus G-CSF, in older men with metastatic castration-resistant prostate cancer (mCRPC). In this prospective, randomized phase 3 trial, CBZ q2w plus G-CSF maintained HRQoL and did not deteriorate pain intensity in mCRPC patients who had previously progressed under docetaxel and at least one novel androgen receptor pathway inhibitor. CBZ q2w plus G-CSF could increase the number of patients with mCRPC eligible for chemotherapy and enable a more patient-centered approach.

Published
2024
Full Text
View/download PDF

99. Third- and fourth-line treatment in patients with RCC: Results of a prospective multicentric non-randomised study (IVOIRE study).

Author

Voog, Eric, primary, Campillo-Gimenez, Boris, additional, El Kouri, Claude, additional, Priou, Frank, additional, Laguerre, Brigitte, additional, Joly, Florence, additional, Merrer, Jacques, additional, Delecroix, Valérie, additional, Le Rol, Annick, additional, Delva, Remy, additional, Malhaire, Jean-pierre, additional, Elhannani, Chaza, additional, Pfister, Christian, additional, Rolland, Frederic, additional, Cojocarasu, Oana, additional, Cumin, Isabelle, additional, Monpetit, Erik, additional, Deniel Lagadec, Delphine, additional, Marhuenda, Fanny, additional, and Grude, Francoise, additional

Published
2016
Full Text
View/download PDF

100. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation

Author

Weisel, Katja, primary, Doyen, Chantal, additional, Dimopoulos, Meletios, additional, Yee, Adrian, additional, Lahuerta, Juan José, additional, Martin, Amber, additional, Travers, Karin, additional, Druyts, Eric, additional, Toor, Kabirraaj, additional, Abildgaard, Niels, additional, Lu, Jin, additional, Van Droogenbroeck, Jan, additional, Geraldes, Catarina, additional, Petrini, Mario, additional, Voillat, Laurent, additional, Voog, Eric, additional, and Facon, Thierry, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results